Obicetrapib has been studied in 30 papers since 2023: 9 trials in people, 1 in animals, 20 reviews; 22 in the past year. Its furthest trials in people are at phase 3. The newest story, Oct 24, 2026: “Obicetrapib did not raise blood sugar in pooled trials”.
Obicetrapib slows plasma p-Tau217 increases in human trials in atherosclerotic cardiovascular disease; independent labs reproduce LDL reductions and HDL increases in humans. Adverse-event results generally show no clear effect, but a review reports fewer events. Authors report developer ties; registered trials across uses are company-sponsored, and some ended over a year ago without posted results.
54 findings in 23 papers from 2025 to 2026, 8 of them since April 2026
Independent labs found the same change in people. 12 independent labs in 8 countries; 19 trials, 5 about aging, 3 with no results posted.
“Obicetrapib also showed substantial improvements in HDL-C and ApoB.”
Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
12 independent labs in 8 countries
1 finding against
19 trials, 5 about aging, 3 with no results posted
Obicetrapib decreases LDL cholesterol in humans (statin-treated adults) (MD -27.29 mg/dL; 95% CI -33.65 to -20.93).
“Obicetrapib, compared to placebo, was associated with a significantly greater reduction in LDL-C (MD: -27.29 mg/dL; 95% CI: -33.65 to -20.93; P < 0.0001)”
Obicetrapib decreases LDL cholesterol in humans (high-risk ASCVD patients on maximally tolerated lipid lowering therapy) (-31.75%).
“Obicetrapib significantly reduced LDL-C (-31.75%), non-HDL-C (-29.35%), triglyceride (-5.61%), Lp(a) (-35.67%), ApoB (-19.37%), and increased HDL-C (+125.94%) with no difference in total cholesterol levels.”
Obicetrapib showed no clear effect on adverse events in humans (statin-treated adults).
“there was no significant difference in total adverse events (AEs) (P= 0.4124), serious AEs (P= 0.3712), and AEs leading to discontinuation of medication (P=0.4035)”
Obicetrapib showed no clear effect on adverse events in patients with dyslipidemia or ASCVD, pooled from RCTs (RR 0.96 (95% CI 0.76 to 1.21) for any adverse event).
“Obicetrapib demonstrated a safety profile comparable to placebo.”
Reviewin patients with dyslipidemia or ASCVD, pooled from RCTsn = 3,483
Studies link obicetrapib with 3 measures: new-onset diabetes, tolerability and adverse events.
New-onset diabetes
↓downin humans1OR 0.69
1 study
Obicetrapib lowers the risk of new-onset diabetes in humans (Without diabetes at baseline; compared with placebo) (6.4% versus 8.5%; adjusted OR 0.69, 95% CI 0.47-1.03).
“NoD occurred in 6.4% (obicetrapib) versus 8.5% (placebo) (adjusted OR 0.69, 95% CI 0.47-1.03), directionally consistent across glycaemic strata.”
Human trialWithout diabetes at baseline; compared with placebo10 mg52 weeks38.8% womensn = 1,700
Over 52 weeks, diabetes developed in 6.4% taking obicetrapib versus 8.5% taking placebo, but the results did not rule out no difference.Over 52 weeks, diabetes developed in 6.4% taking obicetrapib versus 8.5% taking placebo, but the results did not rule out no difference.